709 filings
Page 5 of 36
8-K
tzl2 nf1z5gz
13 May 21
Viveve Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:03pm
8-K
nw8q1xu 60
11 May 21
Viveve Announces Adjournment of Annual Meeting
12:34pm
DEFA14A
m3k 99hhgdsr
11 May 21
Additional proxy soliciting materials
12:32pm
424B3
hxgakxdr
20 Apr 21
Prospectus supplement
4:49pm
EFFECT
8uzjwgpn02cn1pnhup7w
20 Apr 21
Notice of effectiveness
12:15am
CORRESP
zhpwbr5mwqp8w
15 Apr 21
Correspondence with SEC
12:00am
UPLOAD
sxbd00q
7 Apr 21
Letter from SEC
12:00am
8-K
l66qsdq ic
1 Apr 21
Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan
8:29am
8-K
bto52
31 Mar 21
Entry into a Material Definitive Agreement
4:20pm
S-8
4a3es
31 Mar 21
Registration of securities for employees
4:18pm
8-K
s8fc8msjypc98 ugr
18 Mar 21
Viveve Reports Full Year 2020 Financial Results and Provides Corporate Update
4:03pm
8-K
0wixve ysg1ioxk2b3ei
18 Feb 21
Viveve Announces Preliminary Topline Financial Results for Fourth Quarter 2020
4:03pm
8-K
kvnpz6cj 751rr
2 Feb 21
Viveve Announces Expansion of IP Portfolio with Issuance of S. Korean Patent
8:29am
8-K
c3cxan11
21 Jan 21
Viveve Announces Initiation of Pivotal U.S. PURSUIT Trial in Stress Urinary Incontinence
8:29am
8-K
ufo0k0v i6pan
19 Jan 21
Viveve Announces Closing of an Upsized $27.6 Million Underwritten Public Offering and Exercise of Over-allotment Option
4:16pm
424B4
7pkvoakmlezv
14 Jan 21
Prospectus supplement with pricing info
5:04pm
EFFECT
4dh a1nxe7zdyoh75ct
14 Jan 21
Notice of effectiveness
12:15am